The purpose of this study was to profile altered patterns of gene expression that characterize degenerative ascending thoracic aortic aneurysms and to compare these patterns with those observed for infrarenal abdominal aortic aneurysms.
D
egenerative aortic aneurysms represent a relatively common condition responsible for considerable cardiovascular morbidity and mortality. Although aneurysms may arise at any site along the course of the aorta, they most frequently occur in the infrarenal abdominal aorta or the descending portion of the thoracic aorta. The ascending thoracic aorta is another common location for aortic aneurysms, which may develop in association with hypertension and spontaneous (type A) aortic dissection, congenital valvular abnormalities (eg, bicuspid aortic valves [1] [2] [3] , and inherited connective tissue disorders (eg, Ehlers-Danlos syndrome type IV, 4 Marfan syndrome, 5 and other fibrillinopathies 6, 7 ). Genetic linkage studies have also revealed several new chromosomal loci associated with familial forms of thoracic aortic aneurysm and dissection, including a locus at 11q23.2-q24 and another at 5q13-14. 8, 9 Although candidate genes at each of these loci have been identified and examined, the genes responsible for aortic disease in these families have not yet been identified. Thus, despite significant progress during the past decade toward understanding the pathogenesis of aneurysmal disease, the specific factors causing aneurysmal degeneration in various locations remain unresolved.
Although it might be assumed that the pathophysiology of aortic aneurysms is homogeneous regardless of location, the histopathologic features of thoracic aortic aneurysms (TAAs) are quite different from those that characterize abdominal aortic aneurysms (AAAs). The microscopic findings in TAAs are most frequently described by the term "cystic medial necrosis," reflecting a noninflammatory loss of medial smooth muscle cells (SMCs), fragmentation of elastic fibers, and mucoid degeneration. 10, 11 In contrast, the histopathologic features of AAAs are dominated by severe intimal atherosclerosis, chronic transmural inflammation, and destructive remodeling of the elastic media. 12, 13 Although it is clear that each of these pathologic patterns can be associated with aneurysm formation, it is uncertain how they are related to the underlying etiology and pathophysiology of aortic disease arising in these two different locations. 14 Further evidence suggests that the cellular and molecular mechanisms underlying various forms of aneurysmal disease may also be different. Studies on human and experimental AAAs have focused on increased expression and tissue localization of elastin-and collagen-degrading enzymes, particularly matrix metalloproteinases (MMPs), cysteine proteases, and their respective inhibitors. [15] [16] [17] [18] Genes encoding a number of proinflammatory cytokines, chemotactic factors, and cell adhesion molecules have also been implicated in AAAs, 19 and depletion of vascular SMCs may have an important influence the process of vascular remodeling that occurs during aneurysmal degeneration. 20, 21 Studies focusing on TAAs have indicated that cystic medial necrosis is also associated with elastin degradation and fragmentation, 22, 23 SMC depletion and apoptosis, 24 and increased expression of at least some MMPs. 25, 26 . However, the absence of a significant inflammatory response implies alternative mechanisms of aneurysm formation in TAAs versus AAAs, perhaps related to the different embryologic origin of cells populating the ascending and infrarenal aorta, differing structural properties and propensities toward atherosclerotic degeneration, or the distinct hemodynamic conditions that distinguish these two areas. Despite ongoing investigations regarding the fundamental mechanisms responsible for aneurysmal degeneration, the spectrum of molecular alterations that may occur in aneurysms at different sites remains unknown.
The development of microchip-and membrane-based complementary DNA (cDNA) arrays has recently made it possible to examine simultaneous expression of thousands of gene products in the same experiment. [27] [28] [29] [30] [31] Microarray techniques have been applied to diverse disease processes, including human atherosclerosis and AAAs, yielding valuable insights into the pathologic profiles of altered gene expression in these conditions. [32] [33] [34] Given the potential discoveries that might arise from more comprehensive understanding of altered gene expression in different forms of aneurysmal disease, the purpose of this study was to establish a transcriptional profile of aortic wall gene expression that occurs in TAAs relative to normal ascending aorta (NTA). A second goal of this study was to compare altered patterns of gene expression between TAAs and AAAs to determine the similarities and differences that may exist between these two conditions.
Methods

Aortic Tissues
Full-thickness aortic wall specimens were obtained from 4 patients undergoing elective surgical repair of asymptomatic TAAs (2 men and 2 women, ages 49, 78, 82, and 52 years, mean age 65.3 Ϯ 4.3 years). The mean aneurysm size was 6.0 Ϯ 0.4 cm by computed tomography (5.0, 5.0, 8.0, and 6.0 cm). None of these lesions were associated with aortic dissection, congenital aortic valve abnormalities, inherited connective tissue disorders, or familial forms of aneurysmal disease, and no patients had AAAs. For comparison, 4 full-thickness specimens of NTA were obtained from cadaveric organ transplant donors without visible evidence of atherosclerosis (2 men and 2 women, ages 25, 40, 59 , and 38 years, mean age 40.5 Ϯ 3.5 years).
A second series of full-thickness aortic wall specimens was obtained from 4 patients undergoing elective repair of asymptomatic AAAs, including 2 men and 2 women (ages 84, 80, 76, and 57 years, mean age 74.3 Ϯ 6.0 years). The mean aneurysm size was 5.7 Ϯ 0.3 cm by computed tomography (5.5, 5.1, 6.3, and 6.0 cm). None of the patients had "inflammatory" AAAs or aneurysms elsewhere. For comparison, specimens of normal infrarenal abdominal aorta (NAA) without visible evidence of atherosclerosis were obtained from 4 cadaveric organ transplant donors (3 men and 1 woman, ages 43, 18, 14, and 36 years, mean age 27.8 Ϯ 7.0 years).
All tissue specimens were snap-frozen in liquid nitrogen immediately on procurement and stored at Ϫ70°C before nucleic acid extraction. All tissues were obtained with approval by the Washington University School of Medicine human research subjects committee.
RNA Samples
Each aortic tissue sample (n ϭ 16) was pulverized under liquid nitrogen, and total RNA was isolated with Trizol reagent (Gibco BRL, Grand Island, NY). 35, 36 RNA samples were further extracted with phenol and chloroform to eliminate excess protein, and residual DNA contamination was eliminated with RQ1 ribonucleasefree deoxyribonuclease (Promega Corporation, Madison, Wis). In some cases the samples were enriched for messenger RNA by incubation with streptavidin-coated magnetic beads and biotinylated oligodeoxythymidine (Atlas Pure Total RNA Labeling System; Clontech, Palo Alto, Calif).
Preparation of Radiolabeled cDNA and Membrane Hybridization
Radiolabeled cDNA was prepared with reagents and protocols provided with the AtlasArray Human 1.2 I cDNA Expression Array kit from CLONTECH (CLONTECH Laboratories, Inc, Palo Alto, Calif), as previously described elsewhere. 33 For each of the 16 samples, 5 g total RNA was incubated with a mixture of array-specific oligonucleotide primers and 400 units of Superscript II reverse transcriptase (Gibco) in the presence of deoxyadenosine triphosphate labeled with phosphorus 32 (Amersham Pharmacia Biotech, Piscataway, NJ). Labeled cDNA samples were purified by column chromatography to remove unincorporated isotope before use. Each cDNA sample was mixed into hybridization buffer (ExpressHyb; CLONTECH) and then incubated overnight at 68°C with a nylon membrane containing bound cDNA clones corresponding to 1185 known genes (AtlasArray Human 1.2 I; CLON-TECH). Membranes were washed according to the manufacturer's protocol, exposed to a phosphor screen (Eastman Kodak Company, Rochester, NY), and subsequently scanned (Molecular Dynamics, Inc, Sunnyvale, Calif). Densitometry readings for each gene were obtained with AtlasImage 1.01a (CLONTECH) and adjusted for the background density adjacent to each immobilized target cDNA on the same membrane.
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Data Analysis
The relative signal intensity for each gene on a given membrane was calculated as a fraction of the total signal intensity for all genes on the same membrane. The entire data set of adjusted intensity levels was entered into a commercially available data analysis and display platform specifically designed for high-density genomic expression studies (GeneSpring 4.0.4; Silicon Genetics, Redwood, Calif). Data were thereafter accessible for both mathematic computations and a number of different color graphic analytic display options, including the construction of experimental gene trees (dendrograms), self-organizing maps, statistical comparisons, and hierarchic cluster analysis (for reviews of these techniques, see Eisen and colleagues 29 and Lockhart and coworkers 31 and references contained therein). For each gene represented on the microarray, the mean ratio of expression (or fold change) in aneurysmal tissue was calculated by comparison with the mean values obtained for normal aorta from the same location (TAAs vs NTA and AAAs vs NAA). The data set was then examined with a parametric comparisons test to identify genes exhibiting different levels of expression between aneurysms and normal aorta. 29, 31 The two lists of differentially expressed genes were then compared to identify similarities and differences in the patterns of altered gene expression between TAAs and AAAs. To examine the consistency of changes in gene expression within the specimens from each group, the upper limit of normal expression was determined as the mean plus 2 SD of values obtained for the 4 normal aorta specimens. For genes reported to be expressed at increased levels, the number of individual aneurysm specimens exhibiting expression above the upper limit of normal was determined and recorded as a percentage of the total (n ϭ 4) for each group. A similar analysis was performed for genes reported to be expressed at decreased levels, by determining the percentage of aneurysm specimens in which expression was below the lower limit of normal (mean minus 2 SD).
Reverse Transcription-Quantitative Polymerase Chain Reaction
To independently confirm results obtained by cDNA microarray analysis, the relative expression patterns of 9 selected genes were also measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays. Reverse transcription was performed with 1 g total RNA isolated from each aortic tissue sample (n ϭ 16) along with a GeneAmp 2400 thermal cycler and reagents from PE Biosystems (5.5-mmol/L magnesium chloride, 0.5-mol/L deoxyribonucleoside triphosphates, 1.25-U/L MultiScribe Reverse Transcriptase, and 2.5-mol/L random hexamers; PE Biosystems, Foster City, Calif). The cDNA samples were used for real-time detection of PCR amplification with SYBR Green, a fluorescent DNA binding dye (GeneAmp 5700 Sequence Detection System; PE Biosystems), as previously described elsewhere. 36 Primer pairs were selected with PrimerExpress version 1.6 software (PE Biosystems) to amplify the following gene products: MMP-9/gelatinase-B (GenBank J05070), interleukin (IL) 6 signal transducer gp130 (GenBank M57230), v-yes-1 Yamaguchi sarcoma virus-related oncogene (GenBank M16038), apolipoprotein E (GenBank M12529), IL-8 (GenBank Y00787), IL-1␤ (GenBank K02770), tumor necrosis factor (TNF) ␣ (GenBank X01394), vascular cell adhesion molecule 1 (GenBank M30257), cathepsin D (GenBank M11233), and ␤-actin (GenBank X00351).
All real-time polymerase chain reactions (50 L) were performed in duplicate with 10 ng cDNA and kit reagents, with initial incubations at 50°C (2 minutes) and 95°C (10 minutes) for AmpErase and AmpliTaq Gold activation, respectively, followed by 40 cycles of polymerase chain reaction (95°C for 15 seconds alternating with 60°C for 1 minute). Direct detection of reaction products was monitored by measuring the increase in fluorescence caused by the binding of SYBR Green I to double-stranded DNA products, along with an internal reference standard (ROX). Fluorescence signals were analyzed with the GeneAmp 5700 Sequence Detection System software (SDS version 1.3; PE Biosystems) according to the manufacturer's recommendations. All quantitative results were normalized to the mean concentration of ␤-actin messenger RNA to account for variability in the quality of total RNA and the efficiency of reverse transcription between samples. For each gene, statistical differences in expression between TAAs and NTA and between AAAs and NAA were analyzed by the paired Student t test.
Results
Morphologic Appearance of Aneurysmal Tissues
Light microscopy of TAA tissues revealed disruption and disorganization of medial elastic fibers in the absence of significant inflammatory changes, along with areas of ground substance accumulation considered characteristic of cystic medial necrosis ( Figure 1 ). In contrast, AAAs were characterized by more extreme destruction of medial elastic fibers with replacement by a fibrocollagenous extracellular matrix and depletion of medial SMCs. AAAs also exhibited infiltration of the media and adventitia by mononuclear inflammatory cells, often in direct association with degenerating elastic fibers ( Figure 1 ).
Microarray Data
Representative hybridization blots for microarrays prepared from specimens of aneurysmal and normal thoracic aorta are shown in Figure 2 . After phosphoimaging to quantify the relative expression level of each gene, data were corrected for the adjacent background intensity and normalized as a fraction of the total intensity observed on the entire blot. The complete data sets (adjusted intensities for each gene on each of 16 different arrays) were then entered into the GeneSpring program for further analysis. Figure 2 , B, illustrates a color display map depicting the relative levels of expression for all 1185 genes on the array in each sample of TAAs and NTA.
Gene Expression Profiles of Aneurysmal Tissues
One hundred twelve of 1185 genes represented on the microarray (9.5%) were differentially expressed between TAAs and NTA (P Ͻ .05), with 105 exhibiting a significant increase in expression and 7 exhibiting a significant decrease ( Table 1 ). The magnitude of increased expression was at least 10-fold greater in TAAs than NTA for 17 of these transcripts, with the greatest increases observed for protein kinase C (PKC) (Ͼ100-fold), uracil-DNA glycosidase (44-fold), lymphotoxin ␤ (41-fold), TNF-␣ (27-fold), and the TNF receptor superfamily member CD27 (18-fold). With regard to the consistency of these results, the alterations described were observed in at least 3 of the 4 individual TAA specimens for 95 of the 112 genes (85%), including 92 of the 105 genes (88%) exhibiting increased expression and 3 of the 7 genes (43%) exhibiting decreased expression (Table 1) .
One hundred four of 1185 genes (8.8%) were differentially expressed between AAAs and NAA (P Ͻ .05), with 65 exhibiting a significant increase in expression and 39 exhibiting a significant decrease (Table 2 ). Only 6 of these transcripts were increased greater than 10-fold between 
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AAAs and NAA, including MMP-9/gelatinase B (86-fold), CD86/B7-2 antigen (43-fold), bystin-like (41-fold), apolipoprotein E (15-fold), integrin ␤ 2 (13-fold), and nonreceptor tyrosine kinase 1 (12-fold). Sixty-six of the 104 genes (63%) exhibited the alterations described in at least 3 of the 4 individual AAA specimens, including 50 of the 66 genes (76%) exhibiting increased expression and 17 of the 39 genes (44%) exhibiting decreased expression (Table 2) .
Parallel analyses between aneurysmal and normal aortic tissues from each location are summarized by the Venn diagram shown in Figure 3 , illustrating that the patterns of altered gene expression were quite dissimilar between TAAs and AAAs. It is notable that quantitative increases in expression for 97 genes were found to be unique to TAAs, whereas increases in expression for 61 genes were found to be unique to AAAs; similarly, decreases in expression for 7 genes were unique to TAAs and decreases in 35 gene products were unique to AAAs. Although 8 additional transcripts were significantly altered in both TAAs and AAAs, these alterations were directionally concordant for only 4 genes: MMP-9/gelatinase B, v-yes-1, mitogen-activated protein kinase-9, and intracellular adhesion molecule 1/CD54 (all increased in both TAAs and AAAs). In contrast, the remaining genes were altered in a directionally discordant manner, with all 4 being significantly increased in TAAs and significantly decreased in AAAs (N-acetyltransferase-2, IL-6 signal transducer gp130, mitogen-activated protein kinase kinase-5, and IL enhancer binding factor-1).
RT-qPCR
To validate the results of cDNA microarray analysis, the patterns of messenger RNA expression for a series of selected genes were independently examined with real-time RT-qPCR. As shown in Table 3 
Discussion
To better understand cellular and molecular changes that accompany aneurysm development, cDNA microarrays have been used to profile differences in gene expression between normal human aorta and AAAs. 33, 34 To the best of our knowledge, this investigation represents the first application of high-throughput transcriptional profiling to degenerative aneurysms of the ascending thoracic aorta, thereby providing some initial insights into molecular similarities and differences that may exist between TAAs and AAAs.
The most important observations arising from this study are as follows: (1) TAAs are characterized by significant alterations in expression for at least 112 genes relative to NTA; (2) the altered pattern of gene expression observed in TAAs is distinguishable from that observed in AAAs with respect to at least 208 genes, of which 101 are increased and 7 decreased in TAAs but not in AAAs and 61 are increased and 39 decreased in AAAs but not TAAs; (3) at least 8 genes exhibit altered expression in both TAAs and AAAs, including 4 with directionally concordant and 4 with directionally discordant changes; and (4) the greatest increases in gene expression in TAAs were observed for the and isoforms of PKC, uracil-DNA glycosylase (a DNA repair enzyme), lymphotoxin-␤, TNF-␣, and CD27 (TNF receptor superfamily member-7), whereas the greatest changes in AAAs were for MMP-9/gelatinase B, CD86/B7-2 antigen, bystin-like, apolipoprotein E, integrins ␤ 2 and ␤ 8 , nonreceptor tyrosine kinase 1, Janus kinase 3, IL-8, and PKC-␦. These findings support the hypothesis that TAAs and AAAs are fundamentally different pathophysiologic entities at a molecular level, probably reflecting distinct mechanisms of disease.
In a study of this nature, it is tempting to speculate that individual genes exhibiting altered levels of expression in aneurysmal tissues might be related to the pathophysiologic events underlying aneurysm formation. However, it is important to emphasize first that in this study we examined only established "end-stage" aneurysmal tissues from lesions advanced enough to require elective repair, and second that these aneurysmal tissues were evaluated against normal aortic tissues from comparatively young, healthy, cadaveric organ transplant donors as control preparations. The relative levels of gene expression found in these tissues thus may reflect alterations related to differences in age, microscopic atherosclerotic vascular disease, hemodynamic stresses, and other systemic factors, as well as the presence of aneurysmal degeneration. Furthermore, the alterations described in these established aneurysms do not necessarily provide insight into transcriptional alterations that might occur at earlier stages of disease, only those present in lesions that have enlarged enough to require repair. Although altered gene expression in these tissues may actually be more relevant to the potential clinical complications of 
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aneurysmal disease (expansion and rupture) than those that might exist during early stages of aneurysm formation, it is also clear that the transcriptional alterations identified in this study will need to be confirmed at the protein level, proceeding thereafter to functional assessment of their relevance in in vivo model systems. Nonetheless, with these limitations in mind, the expression profiles derived from this study provide a valuable start toward evaluating gene expression patterns that characterize established aneurysmal disease in the thoracic and abdominal aorta and, perhaps of equal importance, determining how such patterns differ between TAAs and AAAs. Not surprisingly, many of the genes altered in TAAs and AAAs are involved in intracellular signal transduction and transcriptional activation pathways. The differences between TAAs and AAAs may therefore reflect either the presence or absence of different cell types or the dominance of different cellular activation and signaling pathways in each disease. For example, two particular isoforms of PKC were expressed at relatively high levels in TAAs versus NTA, PKC-and PKC-(Ͼ100-fold and 14-fold, respectively), whereas AAAs were associated with a 7-fold increase in expression of PKC-␦ but no significant alterations in other PKC isoforms. Although regulation of PKC activity occurs largely through phosphorylation events by upstream mediators of cell activation, the dominant presence of certain isoforms may influence downstream events by determining how cells respond to PKC activation. 37, 38 With respect to other functionally-related groups of genes, Table 1 reveals that TAAs were associated with pronounced increases in the expression of genes involved in regulating cell survival, proliferation, and programmed cell death, including the DNA repair enzyme uracil-DNA glycosylase (44-fold), 39 lymphotoxins ␣ (8-fold) and ␤ (41-fold), 40 TNF-␣ (27-fold), CD27 (a TNF receptor superfamily member, 18-fold), 41 platelet-derived growth factor receptor ␣ (11-fold), early growth response 1 (10-fold), 42 , cyclins D2 (5-fold) and D3 (4-fold), jun D (7-fold), IL-1␤ (5-fold), and the IL-1␤ converting enzyme homolog ICE-LAP3 (6-fold).
43 If verified at the protein level, the increased local production of soluble cytotoxic mediators, such as TNF-␣ and IL-1␤, may be particularly relevant to the medial SMC dysfunction and depletion observed in TAAs. Indeed, several reports have suggested that programmed cell death may play a role in the medial degeneration observed in TAAs, 24 and it is recognized that both TNF-␣ and IL-1␤ are potent inducers of apoptosis and nitric oxide production in cultured vascular SMCs, particularly when acting in combination. 44, 45 Table 2 demonstrates that AAAs were associated with increased expression of a number of genes related to atherosclerosis and chronic inflammation that were not increased in TAAs, such as those encoding the T-cell costimulatory molecule CD86/B7-2 antigen (43-fold), 46 apoplipoprotein E (15-fold), IL-8 (7-fold), GATA-3 (7-fold), 47 nuclear factor of activated T cells (6-fold), 48, 49 myeloid cell nuclear differentiating antigen (5-fold), macrophage stimulating 1 (4-fold), nuclear factor B p105 (4-fold), inducible nitric oxide synthase (nitric oxide synthase II, 3-fold), urinary-type plasminogen activator receptor (4-fold), and thrombin receptor (4-fold). Genes encoding a number of cell adhesion molecules were also selectively increased in AAAs, such as integrins ␤ 2 (13-fold), ␤ 8 (8-fold), ␣ 4 (6-fold), and ␣ L (4-fold), as well as selectin E (6-fold). Furthermore, it is notable that AAAs were associated with significantly decreased expression of growth arrest and DNA damage inducible 45 (9-fold decrease), 50 smooth muscle and nonmuscle myosin light chain kinase (20-fold decrease), and transforming growth factor ␤ receptor type I (50-fold decrease), which may all reflect the pronounced SMC depletion in AAAs. Perhaps the most important alteration common to both TAAs and AAAs was the marked increase in expression of MMP-9/gelatinase B (9-fold in TAAs vs NTA and 86-fold in AAAs vs NAA), an observation consistent with previous studies demonstrating that production of MMP-9 is increased in TAAs and dissections and in AAAs. [51] [52] [53] MMP-9 is thought to contribute to elastin degradation in aneurysmal disease, because it exhibits enzymatic activity against elastic fibers and other extracellular matrix proteins and because it is produced by medial SMC and aneurysm-infiltrating macrophages. 52, 53 It has also been shown that MMP-9 is overexpressed in various experimental animal models of AAAs, that MMP inhibitors suppress development of experimental AAAs in rats and mice, and that mice lacking MMP-9 are resistant to aneurysm development. 35, [54] [55] [56] [57] In the context of these observations, it appears likely that increased expression of MMP-9 plays a central role in the destructive remodeling of the elastic media associated with aortic aneurysms, regardless of their location or initiating etiology.
Although the clinical significance of this work is yet unknown, the altered patterns of gene expression identified here will provide a valuable foundation for further investigations into the pathobiology of aortic aneurysmal disease. This study also demonstrates that significant heterogeneity exists between TAAs and AAAs at the molecular level and illustrates the use of high-throughput cDNA microarrays to generate novel information. Further applications of gene expression profiling can be expected to substantially enhance our understanding of the diverse processes involved in aneurysmal degeneration.
